<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711418165</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711418165</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Blood pressure</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Dimitrov</surname><given-names>Yves</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711418165">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Baguet</surname><given-names>Jean-Philippe</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711418165">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hottelart</surname><given-names>Carine</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711418165">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Marboeuf</surname><given-names>Philippe</given-names></name>
<xref ref-type="aff" rid="aff4-1741826711418165">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tartiere</surname><given-names>Jean-Michel</given-names></name>
<xref ref-type="aff" rid="aff5-1741826711418165">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ducher</surname><given-names>Michel</given-names></name>
<xref ref-type="aff" rid="aff6-1741826711418165">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Fauvel</surname><given-names>Jean-Pierre</given-names></name>
<xref ref-type="aff" rid="aff6-1741826711418165">6</xref>
<xref ref-type="corresp" rid="corresp1-1741826711418165"/>
</contrib>
</contrib-group>
<aff id="aff1-1741826711418165"><label>1</label>Club des jeunes hypertensiologues, Haguenau, France.</aff>
<aff id="aff2-1741826711418165"><label>2</label>Club des jeunes hypertensiologues, Grenoble, France.</aff>
<aff id="aff3-1741826711418165"><label>3</label>Club des jeunes hypertensiologues, Limoges, France.</aff>
<aff id="aff4-1741826711418165"><label>4</label>Club des jeunes hypertensiologues, Lille, France.</aff>
<aff id="aff5-1741826711418165"><label>5</label>Club des jeunes hypertensiologues, Toulon, France.</aff>
<aff id="aff6-1741826711418165"><label>6</label>Club des jeunes hypertensiologues, Lyon, France.</aff>
<author-notes>
<corresp id="corresp1-1741826711418165">Jean-Pierre Fauvel, Hôpital Edouard Herriot, Department of Nephrology and Hypertension, 5 place Arsonval, 69437 Lyon Cedex 03, France Email: <email>jean-pierre.fauvel@chu-lyon.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>4</issue>
<fpage>706</fpage>
<lpage>711</lpage>
<history>
<date date-type="received"><day>16</day><month>3</month><year>2011</year></date>
<date date-type="accepted"><day>6</day><month>7</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Background and design:</bold> The effects of aspirin on blood pressure (BP) are controversial and a chronopharmacological effect of aspirin on 24-hour BP was reported recently in otherwise untreated hypertensive patients. The study was designed to test the timing effect of aspirin dosing on 24-hour BP in treated hypertensive patients routinely taking aspirin for cardiovascular prevention.</p>
<p><bold>Method and results:</bold> Seventy-five patients were randomized into two groups. One group was to receive aspirin in the evening then in the morning for 1 month and the other group in the morning then in the evening, following a cross-over design. The principal assessment criterion was 24-hour systolic BP (SBP) measured by 24-hour ambulatory BP monitoring (ABPM). Patients were aged 65 ± 9 years and had been hypertensive for 12 ± 10 years. They were all taking a mean of 2.8 antihypertensive drugs and did not modify their treatment throughout the study. Of the included subjects, 70% were men and 33% were diabetics. Mean 24-hour SBP values were clinically equivalent and were not statistically different, depending on whether the aspirin was taking in the morning or evening (128.3 ± 1.4 vs. 128.3 ± 1.4 mmHg, respectively). Neither was there any significant difference in diurnal and nocturnal SBP or in 24-hour, diurnal, and nocturnal diastolic BP (DBP).</p>
<p><bold>Conclusion:</bold> It does not appear useful to advise patients with long-standing hypertension to modify timing of aspirin intake in order to reduce BP values.</p>
</abstract>
<kwd-group>
<kwd>Ambulatory blood pressure monitoring</kwd>
<kwd>aspirin</kwd>
<kwd>hypertension</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711418165" sec-type="intro"><title>Introduction</title>
<p>Aspirin (acetylsalicylic acid) is used extensively for primary and secondary prophylaxis of cardiovascular events.<sup><xref ref-type="bibr" rid="bibr1-1741826711418165">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr3-1741826711418165">3</xref></sup> Its antiplatelet effect is the principal reason for its efficacy, but aspirin may also lower BP. The first studies in human that investigated the effects of aspirin on BP were observational and/or retrospective studies.<sup><xref ref-type="bibr" rid="bibr4-1741826711418165">4</xref></sup> More recent prospective and randomized studies have evaluated the relationship between intake of aspirin and BP. A non significant effect of aspirin on BP is usually reported.<sup><xref ref-type="bibr" rid="bibr5-1741826711418165">5</xref>–<xref ref-type="bibr" rid="bibr10-1741826711418165">10</xref></sup> Furthermore, a chronopharmacological effect of aspirin on BP in healthy subjects and pregnant women has been reported.<sup><xref ref-type="bibr" rid="bibr11-1741826711418165">11</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr14-1741826711418165">14</xref></sup> In untreated moderately hypertensive patients, 100 mg aspirin in the evening for 2 months reduced SBP and DBP by 6 and 4 mmHg, respectively, in comparison with the same dose administered in the morning.<sup><xref ref-type="bibr" rid="bibr15-1741826711418165">15</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr18-1741826711418165">18</xref></sup> As recommanded by Messerli<sup><xref ref-type="bibr" rid="bibr19-1741826711418165">19</xref></sup> and Bautista and Vera,<sup><xref ref-type="bibr" rid="bibr20-1741826711418165">20</xref></sup> it is necessary to confirm the results of these studies before advising hypertensive patients to take aspirin in the evening. We therefore studied the timing effect of aspirin dosing on BP in hypertensive patients all of whom were treated with aspirin and antihypertensive medication.</p>
</sec>
<sec id="sec2-1741826711418165" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-1741826711418165" sec-type="subjects"><title>Patients</title>
<p>The study was conducted in six hypertension centres and 81 patients (men and women) were included prospectively in compliance with the statistical plan. Inclusion criteria for patients were: treated hypertension, aged more than 18 years, treated by aspirin for cardiovascular risk prevention for at least 6 months. Subjects were randomized into two groups at inclusion. The randomization was stratified by centres in blocks of four patients. In this randomized open-labelled comparative study, one group was to receive aspirin in the evening then in the morning for 1 month and the other group in the morning then in the evening, according to a cross-over design. The dose of aspirin was not modified throughout the 2 months of the study. Patients were advised to take aspirin in the middle of the breakfast (morning intake) or in the middle of the dinner (evening intake). Patients were advised not to change their antihypertensive treatment and/or time of dosing. Nonsteroidal anti-inflammatory drugs were not allowed throughout the study. Biochemical parameters were measured in the laboratory of each centre. Glomerular filtration rate was estimated (eGFR) using the Cockcroft and Gault formula. The study was approved by the Ethics Committee of Strasbourg and all patients were informed of study aims and had signed a written consent form.</p>
</sec>
<sec id="sec4-1741826711418165"><title>Ambulatory blood pressure monitoring</title>
<p>The device used for ambulatory blood pressure monitoring (ABPM) was Spacelabs 90207. BP was measured by the oscillometric method every 20 minutes throughout the day and every 30 minutes throughout the night. The same device was used (series number recorded) for each patient during each ABPM session. Each ABPM recording was validated according to the following quality criteria: cuff size adjusted to arm circumference, controlled calibration of the device (not more than 5 mmHg difference between the first ABPM measurement and concomitant measurement of SBP and DBP with another validated device); duration of recording &gt; 24 hours and including at least 48 valid measurements and no more than two missing time spans. In the event of non-validation, the patient was not asked to repeat ABPM monitoring. For all patients, monitoring was performed during a day of normal activity and not at weekend. The following parameters were recorded: SBP, DBP, and heart rate over 24 hours. Means of each parameter were calculated for the 24-hour recording, diurnal (7:00−22:00) and nocturnal periods (23:00−06:00).</p>
</sec>
<sec id="sec5-1741826711418165"><title>Statistical analysis</title>
<p>The principal assessment criterion was 24-hour SBP measured by ABPM. Secondary criteria were 24-hour DBP, diurnal and nocturnal BP, and office BP. A sample size of 71 subjects was required to show a 4 mmHg difference with a 8.5 mmHg standard deviation, a 5% alpha risk, and a power of 80% for 24-hour SBP according to morning or evening administration of aspirin. To have 71 analysable cases, we planned to include 80 patients. The results of descriptive analysis of collected data are presented as follows: for quantitative variables, mean ± standard error of the mean; for qualitative variables, sample size and percentages. A two-way ANOVA (Medcalc) was used to check the lack of interaction with the order of ABPM mean BP over 24 hours and during diurnal and nocturnal periods. BP values were then compared using a paired t test. Two-way ANOVA were used to analyse influences on 24-hour BP of the following variables: gender, presence of diabetes, chronic renal failure (eGFR lower or higher than 60 ml/min), overweight (three categories of body mass index: &gt;30 kg/m<sup>2</sup>, 25−30 kg/m<sup>2</sup>, and &lt;25 kg/m<sup>2</sup>), aspirin dosage (lower or higher than 75 mg/day) and number of antihypertensive drugs taken. <italic>p</italic> &lt; 0.05 was considered to be significant for the main criterion and <italic>p</italic> &lt; 0.01 was considered to be significant for the multiple comparisons.</p>
</sec>
</sec>
<sec id="sec6-1741826711418165" sec-type="results"><title>Results</title>
<p>Eighty-one hypertensive patients (aged 45−82 years) were included in the study. They all were taking at least one antihypertensive drug. Mean ± SD number of antihypertensive drugs was 2.8 ± 1.2. Thirteen patients were treated by one antihypertensive drug, 17 patients by two drugs, 26 by three drugs, 12 by four drugs, six by five drugs, and one by six drugs. One patient withdrew consent before the first ABPM. The number of BP measurements recorded over 24 hours was insufficient for three patients, and two patients modified their antihypertensive drugs between inclusion and the second ABPM. No subject was excluded due to a modification of time of dosing. The analysis was thus conducted on 75 patients. The principal characteristics of included patients are given in <xref ref-type="table" rid="table1-1741826711418165">Table 1</xref>. Before participating in the study, 24% of the patients took aspirin in the morning, 58% at noon, and 18% in the evening. Distribution of aspirin doses was the following: 48 patients (64%) were taking 75 mg/day, 25 patients (33%) were taking 80−160 mg/day, and two patients (3%) were taking 300 mg/day. Thirty-nine patients were randomized into the group taking aspirin in the morning then in the evening and 36 were randomized into the group with the inversed sequence. Mean ambulatory BP values are given in <xref ref-type="table" rid="table2-1741826711418165">Table 2</xref>. ANOVA showed no administration time effect (<xref ref-type="table" rid="table2-1741826711418165">Table 2</xref>) and no interaction with ABPM repetition effect. No significant difference was observed according to sex, presence of diabetes, body mass index, chronic renal failure (eGFR &lt;60 ml/min), aspirin dosage, or the number of antihypertensive drugs (1−6 tablets/day).
<table-wrap id="table1-1741826711418165" position="float"><label>Table 1.</label><caption><p>Main characteristics of patients (<italic>n</italic> = 75)</p></caption>
<graphic alternate-form-of="table1-1741826711418165" xlink:href="10.1177_1741826711418165-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Study population</th></tr></thead>
<tbody align="left">
<tr>
<td>Males</td>
<td>70</td></tr>
<tr>
<td>Age (years)</td>
<td>65 ± 9</td></tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>28.3 ± 5.4</td></tr>
<tr>
<td>History of hypertension (years)</td>
<td>12 ± 10</td></tr>
<tr>
<td>SBP at consultation (mmHg)</td>
<td>146 ± 15</td></tr>
<tr>
<td>DBP at consultation (mmHg)</td>
<td>79 ± 11</td></tr>
<tr>
<td>HR at consultation (bpm)</td>
<td>71 ± 12</td></tr>
<tr>
<td>Number of antihypertensive drugs</td>
<td>2.8 ± 1.2</td></tr>
<tr>
<td>Mean dosage of aspirin (mg)</td>
<td>106 ± 50</td></tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>187 ± 41</td></tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>52 ± 16</td></tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>107 ± 35</td></tr>
<tr>
<td>eGFR (ml/min)</td>
<td>59 ± 25</td></tr>
<tr>
<td>Proteinuria (g/24 hours)</td>
<td>0.75 ± 1.18</td></tr>
<tr>
<td>Diabetes</td>
<td>33</td></tr>
<tr>
<td>Current smoker</td>
<td>4</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711418165"><p>Values are % or mean ± standard deviation.</p></fn>
<fn id="table-fn2-1741826711418165"><p>DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein; SBP, systolic blood pressure.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1741826711418165" position="float"><label>Table 2.</label><caption><p>Mean ambulatory blood pressures values according to time of aspirin administration</p></caption>
<graphic alternate-form-of="table2-1741826711418165" xlink:href="10.1177_1741826711418165-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Aspirin in the morning (mmHg)</th>
<th>Aspirin in the evening (mmHg)</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td>24-hour SBP</td>
<td>128.3 ± 1.4</td>
<td>128.3 ± 1.4</td>
<td>0.98</td></tr>
<tr>
<td>24-hour DBP</td>
<td>72.5 ± 0.9</td>
<td>72.6 ± 0.9</td>
<td>0.87</td></tr>
<tr>
<td>Diurnal SBP</td>
<td>131.9 ± 1.5</td>
<td>131.2 ± 1.5</td>
<td>0.42</td></tr>
<tr>
<td>Diurnal DBP</td>
<td>75.4 ± 1.0</td>
<td>74.5 ± 1.0</td>
<td>0.11</td></tr>
<tr>
<td>Noctural SBP</td>
<td>121.4 ± 1.7</td>
<td>122.5 ± 1.7</td>
<td>0.31</td></tr>
<tr>
<td>Noctural DBP</td>
<td>66.6 ± 0.9</td>
<td>66.9 ± 0.9</td>
<td>0.62</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711418165"><p>Values are mean ± standard error of the mean. Paired Student’s t-test for comparisons.</p></fn>
<fn id="table-fn4-1741826711418165"><p>DBP, diastolic blood pressure; SBP, systolic blood pressure.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec7-1741826711418165" sec-type="discussion"><title>Discussion</title>
<p>We conducted a prospective, randomized, multicentre study. Our results clearly show that the time of aspirin administration did not significantly modify 24-hour SBP. Neither did we evidence any effect of the time of aspirin administration on 24-hour DBP or on diurnal and nocturnal SBP and DBP. In our study, the time of aspirin administration had no more effect on BP values recorded by ABPM than those usually reported for placebo in placebo-controlled efficacy studies.<sup><xref ref-type="bibr" rid="bibr21-1741826711418165">21</xref></sup></p>
<p>In hypertensive patients, aspirin restores normal endothelial function,<sup><xref ref-type="bibr" rid="bibr22-1741826711418165">22</xref></sup> improves endothelium-dependent relaxation,<sup><xref ref-type="bibr" rid="bibr23-1741826711418165">23</xref>,<xref ref-type="bibr" rid="bibr24-1741826711418165">24</xref>,<xref ref-type="bibr" rid="bibr25-1741826711418165">25</xref></sup> and inhibits smooth muscle cell proliferation.<sup><xref ref-type="bibr" rid="bibr26-1741826711418165">26</xref></sup> Any antihypertensive effect of aspirin could be mediated by stimulation of nitric oxide production,<sup><xref ref-type="bibr" rid="bibr27-1741826711418165">27</xref></sup> by inhibition of sympathetic activity in the hypothalamus,<sup><xref ref-type="bibr" rid="bibr28-1741826711418165">28</xref></sup> and/or by inhibition of the renin−angiotensin−aldosterone system<sup><xref ref-type="bibr" rid="bibr29-1741826711418165">29</xref></sup> and particularly of angiotensin II.<sup><xref ref-type="bibr" rid="bibr30-1741826711418165">30</xref>,<xref ref-type="bibr" rid="bibr31-1741826711418165">31</xref></sup></p>
<p>According to Hermida et al.,<sup><xref ref-type="bibr" rid="bibr32-1741826711418165">32</xref></sup> the latter point could explain the antihypertensive effect of aspirin administered in the evening. Hermida et al. studied the effect of aspirin on BP in healthy subjects,<sup><xref ref-type="bibr" rid="bibr14-1741826711418165">14</xref></sup> pregnant women,<sup><xref ref-type="bibr" rid="bibr12-1741826711418165">12</xref></sup> untreated hypertensive patients,<sup><xref ref-type="bibr" rid="bibr15-1741826711418165">15</xref>,<xref ref-type="bibr" rid="bibr17-1741826711418165">17</xref>,<xref ref-type="bibr" rid="bibr18-1741826711418165">18</xref></sup> and, very recently, on subjects with pre-hypertension.<sup><xref ref-type="bibr" rid="bibr32-1741826711418165">32</xref></sup> All these studies were remarkable in that they pointed to an antihypertensive effect only when aspirin was taken in the evening. In 16 grade-1 hypertensive subjects, aspirin taken at bedtime compared with on awakening significantly diminished 24-hour plasma renin activity and excretion of cortisol, dopamine, and norepinephrine in 24-hour urine without influencing 24-hour BP.<sup><xref ref-type="bibr" rid="bibr33-1741826711418165">33</xref></sup> From these results, it would be logical to extrapolate that if hypertensive patients already taking aspirin for cardioprotection took their aspirin in the evening, this would lower BP. However, all these studies were carried out in highly specific populations which were very different from hypertensive patients consulting in cardiology or nephrology.</p>
<p>We did not find the same results as those reported by Hermida et al., but our study population was very different. The patients included in our study had been taking 2.8 antihypertensive drugs for a mean of 12 years. In the studies conducted by Hermida et al., recently diagnosed hypertensive patients were not receiving any antihypertensive drug.<sup><xref ref-type="bibr" rid="bibr15-1741826711418165">15</xref>,<xref ref-type="bibr" rid="bibr17-1741826711418165">17</xref>,<xref ref-type="bibr" rid="bibr18-1741826711418165">18</xref>,<xref ref-type="bibr" rid="bibr32-1741826711418165">32</xref></sup> Moreover, these younger patients did not present any comorbidity, whereas we had 33% diabetics and 65% renal failure patients. These differences in the population could explain the discrepancies between studies. Nevertheless, multivariate analysis showed no effect of diabetes, renal failure, age, the number of antihypertensive drugs taken, sex, or body mass index on the BP values obtained according to the time of aspirin administration. It is possible that our sample size was too small to show a significant intergroup difference. Our patients had been taking aspirin for a long time and it is possible that the chronopharmacological effect weakens over time. In the earlier studies, aspirin was only taken during the study. In another study, Hermida et al. showed restoration of the nocturnal physiological decrease in BP in untreated moderately hypertensive patients.<sup><xref ref-type="bibr" rid="bibr17-1741826711418165">17</xref></sup> After 3 months’ treatment with 100 mg aspirin administered in the evening, the proportion of non-dippers dropped from 36.6% to 26.7% whereas it remained unchanged when aspirin was administered in the morning. In the group of patients taking aspirin in the evening, 58.3% of non-dippers became dippers. In our study, the time at which aspirin was administered did not modify the dipper/non-dipper status of patients.</p>
<p>The absence of any administration time effect in our study showed that whatever the action mechanism of aspirin, it was no longer effective, perhaps because of the much longer history of hypertension in our study population than in those of Hermida’s studies. This may be associated with irreversible vascular impairment preventing its action or neurohumoral mediators that have lost their nycthemeral cycle and no longer respond to a treatment administered in the evening. In this case, aspirin in the evening will have no more effect than at any other time. At this point, it is important to specify that the aim of our study was not to assess the antihypertensive effect of aspirin as such, but only the effect of administration time. For this purpose, a wash-out period was not included in the design of the study and thus a baseline 24-hour ABPM was not recorded. Furthermore, a wash-out period in patients already taking aspirin for cardiovascular prevention could raise ethical concerns.</p>
<p>To conclude, it does not appear useful to recommend patients with long-standing hypertension and taking aspirin for cardiovascular prophylaxis to take aspirin in the evening to reduce BP values. <xref ref-type="fig" rid="fig1-1741826711418165">Figure 1</xref>.
<fig id="fig1-1741826711418165" position="float"><label>Figure 1.</label><caption><p>Mean 24-hour, diurnal, and nocturnal systolic and diastolic blood pressure when aspirin is taken in the morning or evening. Box plots show mean ± standard deviation and 95% confidence intervals.</p></caption><graphic xlink:href="10.1177_1741826711418165-fig1.tif"/></fig></p>
</sec>
</body>
<back>
<ack><title>Acknowledgements</title>
<p>The authors would like to thank Mrs Lynn Richardson for translation support.</p></ack>
<sec id="sec8-1741826711418165"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec9-1741826711418165"><title>Conflict of interest</title>
<p>None.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711418165"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Gaetano</surname><given-names>G</given-names></name></person-group><collab>Collaborative Group of the Primary Prevention Project</collab>. <article-title>Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice</article-title>. <source>Lancet</source> <year>2001</year>; <volume>357</volume>: <fpage>89</fpage>–<lpage>95</lpage>.</citation></ref>
<ref id="bibr2-1741826711418165"><label>2</label><citation citation-type="journal"><collab>Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk</collab>. <article-title>The Medical Research Council’s General Practice Research Framework</article-title>. <source>Lancet</source> <year>1998</year>; <volume>351</volume>: <fpage>233</fpage>–<lpage>241</lpage>.</citation></ref>
<ref id="bibr3-1741826711418165"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Carruthers</surname><given-names>SG</given-names></name><name><surname>Dahlöf</surname><given-names>B</given-names></name><name><surname>Elmfeldt</surname><given-names>D</given-names></name><name><surname>Julius</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment</article-title>. <source>Lancet</source> <year>1998</year>; <volume>351</volume>: <fpage>1177</fpage>–<lpage>1184</lpage>.</citation></ref>
<ref id="bibr4-1741826711418165"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SL</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name></person-group>. <article-title>The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure levels in adults</article-title>. <source>J Hypertension</source> <year>2006</year>; <volume>24</volume>: <fpage>1457</fpage>–<lpage>1469</lpage>.</citation></ref>
<ref id="bibr5-1741826711418165"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polonia</surname><given-names>J</given-names></name><name><surname>Gama</surname><given-names>G</given-names></name><name><surname>Camões</surname><given-names>I</given-names></name><name><surname>Bernardo</surname><given-names>F</given-names></name><name><surname>Andrade</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Influence of nonsteroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients</article-title>. <source>J Hypertens</source> <year>1995</year>; <volume>13</volume>: <fpage>925</fpage>–<lpage>931</lpage>.</citation></ref>
<ref id="bibr6-1741826711418165"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nawarskas</surname><given-names>JJ</given-names></name><name><surname>Cirigliano</surname><given-names>MD</given-names></name><name><surname>Spinler</surname><given-names>SA</given-names></name></person-group>. <article-title>Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan</article-title>. <source>Am J Hypertens</source> <year>1999</year>; <volume>12</volume>: <fpage>784</fpage>–<lpage>789</lpage>.</citation></ref>
<ref id="bibr7-1741826711418165"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Avanzini</surname><given-names>F</given-names></name><name><surname>Palumbo</surname><given-names>G</given-names></name><name><surname>Alli</surname><given-names>C</given-names></name><name><surname>Roncaglioni</surname><given-names>MC</given-names></name><name><surname>Ronchi</surname><given-names>E</given-names></name><name><surname>Cristofari</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effects of low-dose aspirin on clinic and ambulatory blood-pressure in treated hypertensive patients</article-title>. <source>Am J Hypertens</source> <year>2000</year>; <volume>13</volume>: <fpage>611</fpage>–<lpage>616</lpage>.</citation></ref>
<ref id="bibr8-1741826711418165"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SR</given-names></name><name><surname>Coffman</surname><given-names>TM</given-names></name><name><surname>Svetkey</surname><given-names>LP</given-names></name></person-group>. <article-title>Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril</article-title>. <source>J Am Soc Nephrol</source> <year>1993</year>; <volume>4</volume>: <fpage>1133</fpage>–<lpage>1139</lpage>.</citation></ref>
<ref id="bibr9-1741826711418165"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magagna</surname><given-names>A</given-names></name><name><surname>Abdel-Haq</surname><given-names>B</given-names></name><name><surname>Favilla</surname><given-names>S</given-names></name><name><surname>Taddei</surname><given-names>S</given-names></name><name><surname>Salvetti</surname><given-names>A</given-names></name></person-group>. <article-title>Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients</article-title>. <source>Blood Press</source> <year>1994</year>; <volume>3</volume>: <fpage>236</fpage>–<lpage>241</lpage>.</citation></ref>
<ref id="bibr10-1741826711418165"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Leonetti</surname><given-names>G</given-names></name><name><surname>Rahn</surname><given-names>KH</given-names></name><name><surname>Ruilope</surname><given-names>L</given-names></name><name><surname>Warnold</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy</article-title>. <source>J Hypertens</source> <year>2002</year>; <volume>20</volume>: <fpage>1015</fpage>–<lpage>1022</lpage>.</citation></ref>
<ref id="bibr11-1741826711418165"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Ayala</surname><given-names>DE</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name><name><surname>Mojón</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>I</given-names></name><name><surname>Ucieda</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women</article-title>. <source>Hypertension</source> <year>1997</year>; <volume>30</volume>: <fpage>589</fpage>–<lpage>595</lpage>.</citation></ref>
<ref id="bibr12-1741826711418165"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Ayala</surname><given-names>DE</given-names></name><name><surname>Fernández</surname><given-names>JR</given-names></name><name><surname>Mojón</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>I</given-names></name><name><surname>Silva</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Administration time-dependant effects of aspirin in women at differing risk for preeclampsia</article-title>. <source>Hypertension</source> <year>1999</year>; <volume>34</volume>: <fpage>1016</fpage>–<lpage>1023</lpage>.</citation></ref>
<ref id="bibr13-1741826711418165"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Ayala</surname><given-names>DE</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name></person-group>. <article-title>Administration time-dependent influence of aspirin on blood pressure in pregnant women</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>651</fpage>–<lpage>656</lpage>.</citation></ref>
<ref id="bibr14-1741826711418165"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Ayala</surname><given-names>DE</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name><name><surname>Halberg</surname><given-names>F</given-names></name></person-group>. <article-title>Time-dependent effects of ASA administration on blood pressure in healthy subjects</article-title>. <source>Chronobiologica</source> <year>1994</year>; <volume>21</volume>: <fpage>201</fpage>–<lpage>213</lpage>.</citation></ref>
<ref id="bibr15-1741826711418165"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Calvo</surname><given-names>C</given-names></name><name><surname>Ayala</surname><given-names>DE</given-names></name><name><surname>Domínguez</surname><given-names>MJ</given-names></name><name><surname>Covelo</surname><given-names>M</given-names></name><name><surname>Fernández</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>1259</fpage>–<lpage>1267</lpage>.</citation></ref>
<ref id="bibr16-1741826711418165"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Ayala</surname><given-names>DE</given-names></name><name><surname>Mojon</surname><given-names>A</given-names></name><name><surname>Iglesias</surname><given-names>M</given-names></name></person-group>. <article-title>Influence of aspirin usage on blood pressure: dose and administration-time dependencies</article-title>. <source>Chronobiol Int</source> <year>1997</year>; <volume>14</volume>: <fpage>619</fpage>–<lpage>637</lpage>.</citation></ref>
<ref id="bibr17-1741826711418165"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Calvo</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>JE</given-names></name></person-group>. <article-title>Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>46</volume>: <fpage>975</fpage>–<lpage>983</lpage>.</citation></ref>
<ref id="bibr18-1741826711418165"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Calvo</surname><given-names>C</given-names></name><name><surname>Ayala</surname><given-names>JE</given-names></name><name><surname>Mojón</surname><given-names>A</given-names></name><name><surname>Rodríguez</surname><given-names>M</given-names></name><name><surname>Chayán</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives</article-title>. <source>Hypertension</source> <year>2005</year>; <volume>46</volume>: <fpage>1060</fpage>–<lpage>1068</lpage>.</citation></ref>
<ref id="bibr19-1741826711418165"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group>. <article-title>Aspirin: a novel antihypertensive drug? Or two birds with one stone?</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>46</volume>(<issue>6</issue>): <fpage>984</fpage>–<lpage>985</lpage>.</citation></ref>
<ref id="bibr20-1741826711418165"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>LE</given-names></name><name><surname>Vera</surname><given-names>LM</given-names></name></person-group>. <article-title>Antihypertensive effects of aspirin: what is the evidence?</article-title> <source>Curr Hypertens Rep</source> <year>2010</year>; <volume>12</volume>(<issue>4</issue>): <fpage>282</fpage>–<lpage>289</lpage>.</citation></ref>
<ref id="bibr21-1741826711418165"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mansoor</surname><given-names>GA</given-names></name><name><surname>White</surname><given-names>WB</given-names></name></person-group>. <article-title>Contribution of ambulatory blood pressure monitoring to the design and analysis of antihypertensive therapy trials</article-title>. <source>J Cardiovasc Risk</source> <year>1994</year>; <volume>1</volume>: <fpage>136</fpage>–<lpage>142</lpage>.</citation></ref>
<ref id="bibr22-1741826711418165"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>Z</given-names></name><name><surname>Giachini</surname><given-names>FR</given-names></name><name><surname>Tostes</surname><given-names>RC</given-names></name><name><surname>Webb</surname><given-names>RC</given-names></name></person-group>. <article-title>Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation</article-title>. <source>Cardiovasc Res</source> <year>2009</year>; <volume>83</volume>: <fpage>155</fpage>–<lpage>162</lpage>.</citation></ref>
<ref id="bibr23-1741826711418165"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>S</given-names></name><name><surname>Mulcahy</surname><given-names>D</given-names></name><name><surname>Panza</surname><given-names>JA</given-names></name><name><surname>Quyyumi</surname><given-names>AA</given-names></name></person-group>. <article-title>Aspirin improves endothelial dysfunction in atherosclerosis</article-title>. <source>Circulation</source> <year>1998</year>; <volume>97</volume>: <fpage>716</fpage>–<lpage>720</lpage>.</citation></ref>
<ref id="bibr24-1741826711418165"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noon</surname><given-names>JP</given-names></name><name><surname>Hand</surname><given-names>MF</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group>. <article-title>Impairement of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin</article-title>. <source>Cardiovasc Res</source> <year>1998</year>; <volume>38</volume>: <fpage>480</fpage>–<lpage>484</lpage>.</citation></ref>
<ref id="bibr25-1741826711418165"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monobe</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Ohe</surname><given-names>T</given-names></name></person-group>. <article-title>Effects of low-dose aspirin on endothelial function in hypertensive patients</article-title>. <source>Clin Cardiol</source> <year>2001</year>; <volume>24</volume>: <fpage>705</fpage>–<lpage>709</lpage>.</citation></ref>
<ref id="bibr26-1741826711418165"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>M</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>R</given-names></name><name><surname>Matsuhisa</surname><given-names>M</given-names></name><name><surname>Kajimoto</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes</article-title>. <source>Thromb Res</source> <year>2000</year>; <volume>97</volume>: <fpage>239</fpage>–<lpage>245</lpage>.</citation></ref>
<ref id="bibr27-1741826711418165"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taubert</surname><given-names>D</given-names></name><name><surname>Berkels</surname><given-names>R</given-names></name><name><surname>Grosser</surname><given-names>N</given-names></name><name><surname>Schröder</surname><given-names>H</given-names></name><name><surname>Gründemann</surname><given-names>D</given-names></name><name><surname>Schömig</surname><given-names>E</given-names></name></person-group>. <article-title>Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action</article-title>. <source>Br J Pharmacol</source> <year>2004</year>; <volume>143</volume>: <fpage>159</fpage>–<lpage>165</lpage>.</citation></ref>
<ref id="bibr28-1741826711418165"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nye</surname><given-names>EJ</given-names></name><name><surname>Hockings</surname><given-names>GI</given-names></name><name><surname>Grice</surname><given-names>JE</given-names></name><name><surname>Torpy</surname><given-names>DJ</given-names></name><name><surname>Walters</surname><given-names>MM</given-names></name><name><surname>Crosbie</surname><given-names>GV</given-names></name><etal/></person-group>. <article-title>Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans</article-title>. <source>J Clin Endocrinol Metab</source> <year>1997</year>; <volume>82</volume>: <fpage>812</fpage>–<lpage>817</lpage>.</citation></ref>
<ref id="bibr29-1741826711418165"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Harris</surname><given-names>RC</given-names></name></person-group>. <article-title>Cycloxygenase-2 inibition decreases renin content and lower blood pressure in a model of renovascular hypertension</article-title>. <source>Hypertension</source> <year>1999</year>; <volume>34</volume>: <fpage>96</fpage>–<lpage>101</lpage>.</citation></ref>
<ref id="bibr30-1741826711418165"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>De Champlain</surname><given-names>J</given-names></name></person-group>. <article-title>Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats</article-title>. <source>Circulation</source> <year>2002</year>; <volume>105</volume>: <fpage>387</fpage>–<lpage>392</lpage>.</citation></ref>
<ref id="bibr31-1741826711418165"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>De Champlain</surname><given-names>J</given-names></name></person-group>. <article-title>Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats</article-title>. <source>J Hypertension</source> <year>2004</year>; <volume>22</volume>: <fpage>681</fpage>–<lpage>682</lpage>.</citation></ref>
<ref id="bibr32-1741826711418165"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermida</surname><given-names>RC</given-names></name><name><surname>Mojon</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>JR</given-names></name></person-group>. <article-title>Ambulatory blood pressure control with bedtime administration in subjects with prehypertension</article-title>. <source>Am J Hypertens</source> <year>2009</year>; <volume>22</volume>: <fpage>896</fpage>–<lpage>903</lpage>.</citation></ref>
<ref id="bibr33-1741826711418165"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snoep</surname><given-names>JD</given-names></name><name><surname>Hovens</surname><given-names>MM</given-names></name><name><surname>Pasha</surname><given-names>SM</given-names></name><name><surname>Frölich</surname><given-names>M</given-names></name><name><surname>Pijl</surname><given-names>H</given-names></name><name><surname>Tamsma</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines</article-title>. <source>Hypertension</source> <year>2009</year>; <volume>54</volume>: <fpage>1136</fpage>–<lpage>1142</lpage>.</citation></ref>
</ref-list>
</back>
</article>